Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2021-06-16 Capital/Financing Update
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2021, reporting the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering raising approximately $29 million. It includes details about the financing, the use of proceeds, and the placement agent agreement. The document is a current report on a material event, specifically a capital raising transaction. It is not a full financial report, earnings release, or management discussion, but rather an update on financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5237 characters, which is consistent with a detailed 8-K filing for such an event.
2021-06-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of common stock by Enochian Biosciences Inc. It details the terms of a stock offering, including the number of shares, price, placement agent fees, and use of proceeds. The document references the Securities and Exchange Commission (SEC) and includes typical prospectus sections such as risk factors, use of proceeds, plan of distribution, and legal matters. It is not a financial report, earnings release, management discussion, or any other report type but rather a capital raising document. Therefore, it fits the definition of a Capital/Financing Update (CAP).
2021-06-16 English
Director's Dealing 2021
Director's Dealing
2021-06-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 25, 2021, for Enochian Biosciences Inc. The key content is the appointment of a new director, Jayne McNicol, to the Board of Directors and her appointment as Audit Committee Chair. It details her qualifications, independence, and compensation. This is a clear announcement of a change in the company's board of directors. There are no financial statements or detailed financial data, so it is not an annual or interim report. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board and senior management positions.
2021-05-27 English
10-Q
Interim / Quarterly Report Q3 2021
2021-05-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a License Agreement related to research and development activities. It includes details about the agreement terms, payments, and parties involved. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing to disclose a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6770 characters) and detailed description support this classification with high confidence.
2021-04-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.